Counseling cancer patients about herbal medicine

Patient Education and Counseling

Volumn 38, Issue 2, 1999, Pages 109-120

  Smith, Michael ^a   Boon, Heather S ^b,c  

^a CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^b The Michener Institute for Applied Health Sciences   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; Herbal medicine; Patient counseling

Indexed keywords

HOXSEY FORMULA; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; CANCER; CANCER PATIENT; GARLIC; GINSENG; HERB; HERBAL MEDICINE; HUMAN; PATIENT COUNSELING; PHYSICIAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; TEA; VISCUM ALBUM; COUNSELING; DOCTOR PATIENT RELATION; EDUCATION; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; METHODOLOGY; NEOPLASM; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PHYTOTHERAPY; PSYCHOLOGICAL ASPECT; SAFETY; STANDARD;

COMMUNICATION; COUNSELING; HUMANS; INFORMED CONSENT; MEDICINE, HERBAL; NEOPLASMS; PATIENT EDUCATION; PHYSICIAN'S ROLE; PHYSICIAN-PATIENT RELATIONS; PHYTOTHERAPY; SAFETY;

EID: 0032824904     PISSN: 07383991     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-3991(99)00058-0     Document Type: Article

References (141)

1. Brigden M.L. Unproven (questionable) cancer therapies. Western J. Med. 163:1995;463-469.
2. Lerner I.J., Kennedy B.J. The prevalence of questionable methods of cancer treatment in the United States. CA-Cancer J Clin. 42:(3):1992;181-191.
3. Cassileth B.R., Lusk E.J., Strouse T.B., Bodenheimer B.J. Contemporary unorthodox treatments in cancer medicine. Ann Int Med. 101:1984;105-112.
4. Boon, H., Stewart, M., Kennard, M.A., et al., The use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions: submitted, 1999.
5. Yates P., Beadle G., Clavarino A., et al. Patients with terminal cancer who use alternative therapies: Their beliefs and practices. Sociol. Health Illness. 15:(2):1993;117-199.
6. Eisenberg D., Davis R., Ettner S., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow up national survey. J Am Med Assoc. 280:(18):1998;1569-1575.
7. Cassileth B., Chapman C. Alternative cancer medicine: a ten-year update. Cancer Invest. 14:(4):1996;396-404.
8. Lewith G. Cancer. Complement Ther Med. 4:1996;242-246.
9. Ernst E. Complementary treatments for cancer patients. Pharm J. 255:1995;15-17.
10. Ernst E., Cassileth B. Cancer diets: fads and facts. Cancer Prevention Int. 2:1996;181-187.
11. Ren S., Lien E. Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res. 48:1997;147-171.
12. Moss R. Alternative pharmacological and biological treatments for cancer: Ten promising approaches. J Naturopath Med. 6:(1):1996;23-32.
13. Kaegi E. Uncoventional therapies for cancer: 1. Essiac. Can Med Assoc J. 158:(7):1998;897-902.
14. Kaegi E. Unconventional therapies for cancer: 2. Green tea. Can Med Assoc J. 158:(8):1998;1033-1035.
15. Kaegi E. Unconventional therapies for Cancer: 3. Iscador. Can Med Assoc J. 158:(9):1998;1157-1159.
16. Kaegi E. Unconventional therapies for cancer: 4. Hydrazine sulfate. Can Med Assoc J. 158:(10):1998;1327-1330.
17. Kaegi E. Unconventional therapies for cancer: 5. Vitamin A, C and E. Can Med Assoc J. 158:(11):1998;1483-1488.
18. Kaegi E. Unconventional therapies for cancer: 6. 714-X. Can Med Assoc J. 158:(12):1998;1621-1624.
19. Boon, H., Stewart, M., Kennard, M.A., et al., The use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 1999 (submitted).
20. Smith M., Boon H., Burman D. Alternative medicine: a survival guide for pharmacists. Can Pharm J. 129:(6):1996;36-42.
21. Barnes J. Herbal medicine. Pharm J. 260:1998;344-348.
22. Boon, H., Brown, J.B., Gavin, A., Kennard, M.A., Stewart, M., Breast cancer survivors' perceptions of complementary/alternative medicine (CAM): Making the decision to use or not to use. Qualitative Health Care 1999; in press.
23. Shaw D., Leon C., Kolev S., Murray V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Safety. 17:(5):1997;342-356.
24. Ernst E., De Smet P. Risks associated with complementary therapies. Dukes M. Meyler's side effects of drugs. 1996;1427-1454 Elsevier Science B.V, Berlin.
25. Miller L.G. Herbal medicinals. Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Int Med. 158:1998;2200-2211.
26. D'Arcy P. Adverse reactions and interactions with herbal medicines. Part 2 - drug interactions. Adverse Drug React. Toxicol. Rev. 12:(3):1993;147-162.
27. Barnes J., Mills S., Abbot N., Willoughby M., Ernst E. Different standards for reporting ADRs for herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal medicines. Pharm J. 261:(supplement):1998;R21.
28. Keen R., et al. Indian herbal remedies for diabetes as a cause of lead poisoning. Postgrad Med J. 70:1994;113-114.
29. Brown H. The deadliest delusion: unproven methods in the management of cancer. Women Health. 11:(3-4):1986;165-178.
30. Mills S. Safety awareness in complementary medicine. Complement Ther Med. 4:1996;48-51.
31. Ernst E. Competence in complementary medicine. Complement Ther Med. 3:1995;6-8.
32. Stelling K., Salama S., Salib M. Phytotherapy as an adjunct in cancer treatment. Can J Herbalism. Winter:1995;34-36.
33. Zhao K.S., Mancini C., Doria G. Enhancement of the immune response in mice by Astragalus membranaceus extracts. Immunopharmacology. 20:(3):1990;225-233.
34. Sun Y., Chang Y.H., Yu G.Q., et al. Effect of Fu-zheng therapy in the management of malignant diseases. Chin Med J. 61:1981;97-101.
35. Foster S., Chongxi Y. Herbal Emissaries. Bringing Chinese herbs to the west. 1992;Healing Arts Press, Rochester, Vermont.
36. Sun Y., et al. Preliminary observations on the effects of the Chinese medicinal herbs Astragalus membranaceus and Ligustrum lucidum on lymphocyte blastogenic responses. J Biol Resp Modif. 2:1983;227-237.
37. Yang Y.Z., Jin P.Y., Guo Q., et al. Effect of Astragalus membranaceus on natural killer cell activity and induction of α- and γ- interferon in patients with coxsackie B viral myocarditis. Chin Med J. 103:(4):1990;304-307.
38. Zhao K.W., Kong H.Y. Effect of Astragalan on secretion of tumour necrosis factor in human peripheral blood mononuclear cells. Chung-Kuo Chung Hsi i Chieh, Ho Tsa Chih. 13:(5):1993;263-265.
39. Lau B.H., Ruckle H.C., Botolazzo T., Lui P.D. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma. Cancer Biotherapy. 9:(2):1994;153-161.
40. Cha R.J., Zeng D.W., Chang Q.S. Non-surgical treatment of small cell lung cancer with chemo-radio-immunotherapy and traditional Chinese medicine [Chinese]. Chung-Hua Nei Ko Tsa Chih - Chinese Journal of Internal Medicine. 33:(7):1994;462-466.
41. Gray R.E., Greenberg M., Fitch M., Parry N., Douglas M.S., Labrecque M. Perspectives of cancer survivors interested in unconventional therapies. J Psychosocial Oncol. 15:(3/4):1997;149-171.
42. A Guide to Unconventional Cancer Therapies. 1994;Ontario Breast Cancer Information Exchange Project, Toronto, ON.
43. ESSIAC: An Information Package. 1996;Canadian Breast Cancer Research Initiative, Toronto, ON.
44. Locock R.A. Essiac. Can Pharm J. February:(18-19):1997;51.
45. Russfield A.B., McClure C.W. Pathology Report. Project No. C-114 (Essiac Experiments). 1959;Bio-Research Consultants, Inc.
46. Potential Nonspecific Immune Stimulation Effects of Herbal Tea (David Dobbie Product). 1993;Vetrepharm Research.
47. Belkin M., Fitzgerald D.B. Tumour-damaging capacity of plant materials. I. Plants used as cathartics. J Natl Cancer Inst. 13:1952;139-155.
48. Kupchan S.M., Karim A. Tumour Inhibitors: 114. Aloe emodin: antileukemic principle isolated from Rhamnus fangula L. Lloydia. 39:(4):1977;223-224.
49. Lee H., Tsai S.J. Effect of emodin on cooked-food mutagen activation. Food Chemistry and Toxicology. 29:(11):1991;756-770.
50. Ito Y., Maeda S., Sugiyaman T. Suppression of 7,12-dimethylbenz[a]anthracene-induced chromosone aberrations in rat bone marrow cells by vegetable juices. Mutat Res. 172:1986;55-60.
51. Driscoll J.S., Hazard G.F., Wood H.B., Goldin A. Structure-antitumor activity relationships among quinone derivatives. Cancer Chemotherapy Reports. 4:(2):1974;1-27.
52. Masuda T., Ueno Y. Microsomal transformation of emodin into a direct mutagen. Mutat Res. 125:1984;135-144.
53. Morita H., Umeda M., Musuda T., Ueno Y. Cytotoxic and mutagenic effects of emodin on cultured mouse carcinoma. Mutat Res. 204:1988;329-332.
54. Grimminger W., Witthohn K. Analytics of senna drugs with regard to the toxicological discussion of anthranoids. Pharmacology. 47:(Supplement 1):1993;98-109.
55. 14C-aloe emodin after oral administration to male and female rats. Pharmacology. 47:(Supplement 1):1993;110-119.
56. Ma L. Experimental study on the immunomodulatory effects of rhubarb [Chinese-English Absract]. Chung Hsi i Chieh Ho Tsa Chih - Chinese Journal of Modern Developments in Traditional Medicine. 11:(7):1991;418-419.
57. Dombradi C.A., Foldeak S. Screening report on the antitumour activity of purified Arctium lappa extracts. Tumori. 52:1966;173-176.
58. Morita K., Kada T., Namiki M. A desmutagenic factor isolated form burdock (Arctium lappa Linne). Mutat Res. 129:1984;25-31.
59. Ito H. Effects of the antitumor agents from varius natural sources on drug-metabolizing system, phagocytic activity, and complement system in sarcoma 180-bearing mice. Jpn J Pharmacol. 40:1986;435-443.
60. Essiac. Unconventional Cancer Treatments. 1990;US Government Printing Office, Washington, D.C.
61. Essiac International. Essiac Testimonials, 1996.
62. Bryson P., Watanabe A., Rumack B., Murphy R. Burdock root tea poisoning. J Am Med Assoc. 239:(20):1978;2157.
63. Bryson P. Burdock root tea poisoning. J Am Med Assoc. 240:1978;1586.
64. Yun T.-K. Experimental and epidemiological evidence of the cancer-preventative effects of Panax ginseng C.A. Meyer. Nutr Rev. 54:(11):1996;S71-S81.
65. Mochizuki M., Yoo Y., Matsuzawa K. Inhibitory effect of tumor metastasis in mice by saponins, ginsensoside-Rb2, 20(R)-and 20(S)-ginsenoside-Rg3, of red ginseng. Biol Pharm Bulletin. 18:(9):1995;1197-1202.
66. Sato K., Mochizuki M., Saiki I., Yoo Y., Samukawa K., Azuma I. Inhibition of tumor angiogenesis and metastais by a spaonin of Panax ginseng, ginsenoside Rb2. Biol Pharm Bull. 17:(5):1994;635-639.
67. Tode T., Kikuchi Y., Kita T., Hirata J., Imaizumi E., Nagata I. Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice. J Cancer Res Clin Oncol. 120:(1-2):1993;24-26.
68. Lee Y., Chung I., Lee I., Kim K., Hong W., Yun Y. Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng. Anticancer Res. 17:(1A):1997;323-331.
69. Newall C.A., Anderson L.A., Phillipson J.D. Herbal medicines. A guide for health-care professionals. 1996;The Pharmaceutical Press, London.
70. Siegel R.K. Ginseng abuse syndrome. J Am Med Assoc. 241:1979;1644-1645.
71. Baldwin C.A., Anderson L.A., Phillipson J.D. What pharmacists should know about ginseng. Pharm J. 8:1986;583-586.
72. Stockley I. Drug interactions: a source book of adverse interactions, their mechanisms, clinical importance and management. (Third ed ) :1994;Blackwell, London.
73. Shader R.I., Greenblat D.J. Phenelzine and the dream machine-ramblings and reflections. J Clin Psychopharmacol. 5:(2):1985;65.
74. Jones B., Runikis A. Interaction of ginseng with phenelzine. J Clin Psychopharmacology. 7:(3):1987;201-202.
75. Shader R.I., Greenblatt D.J. Bees, ginseng and MAOIs revisited. J Clin Psychopharmacology. 8:(4):1988;235.
76. Liberti L.E., der Marderosian A. Evaluation of commercial ginseng products. J Pharm Sci. 67:1978;1487-1489.
77. Cui J., Garle M., Eneroth P., Bjorkhem I. What do commercial ginseng preparations contain? [letter]. Lancet. 344:(8915):1994;134.
78. Walker A.F. What is in ginseng? [letter; comment]. Lancet. 344:(8922):1994;619.
79. Cui J., Garle M., Eneroth P., Bjorkhem I. Determination of aglycones of ginsenosides in ginseng preparations sold in Sweden and in urine samples from Swedish atheletes consuming ginseng. Scand J Clin Lab Eval. 56:(2):1994;151-160.
80. Farnsworth N.R., Kinghorn A.D., Soejarto D., Waller D.P. Siberian ginseng (Eleuthrococcus senticosus): Current status as an adaptogen. Wagner H., Hikino H., Farnsworth N.R. Economic and Medicinal Plant Research. 1985;155-215 Academic Press, Orlando, Florida.
81. Hacker B., Medon P.J. Cytotoxic effects of Eleutherococcus senticosus aqueous extracts in combination with N6-(delta 2-isopentenyl)-adenosine and 1-beta-D-arabinofuranosylcytosine against L1210 leukemia cells. J Pharm Sci. 73:(2):1984;270-272.
82. Medon P.J., Ferguson P.W., Watson C.F. Effects of Eleutherococcus senticosus extracts on hexobarbital metabolism in vivo and in vitro. J Ethnopharmacol. 10:(2):1984;235-241.
83. Koren G., Randor S., Martin S., Danneman D. Maternal ginseng use associated with neonatal androgenization. J Am Med Assoc. 264:(22):1990;2866.
84. McRae S. Elevated serum digoxin levels in a patient taking digoxin and siberian ginseng. Can Med Assoc J. 155:(3):1996;293-295.
85. Awang D.V. Siberian ginseng toxicity may be case of mistaken identity [comment]. Can Med Assoc J. 155:(9):1996;1237.
86. Ahmad N., Mukhtar H. Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev. 57:(3):1999;78-83.
87. Otsuka T., Ogo T., Eto T., Asano Y., Suganuma M., Niho Y. Growth inhibition of leukemic cells by (-)-epigallocatechin gallate, the main constituent of green tea. Life Sci. 63:(16):1998;1397-1403.
88. Gao Y., Mclaughlin J., Blot W., Ji B., Dai Q. Reduced risk of esopahgeal cancer associated with green tea consumption. J Natl Cancer Inst. 86:(11):1994;855-858.
89. Weisburger J. Physiological and pharmacological effects of Camellia sinensis(tea): first international symposium. Prevent Med. 21:1992;329-530.
90. Yang C., Wang Z. Tea and cancer. J Natl Cancer Inst. 85:(13):1993;1038-1049.
91. Kinjo Y., Cui Y., Akiba S., et al. Mortality risks of oesophageal cancer associated with hot tea, alcohol, tobacco and diet in Japan. J Epidemiol. 8:(4):1998;235-243.
92. Bushman J. Green tea and cancer in humans:a review of the literature. Nutr Cancer. 31:(3):1998;151-159.
93. Fujiki H., Suganuma M., Okabe S., et al. Cancer inhibition by green tea. Mutat Res. 402:(1-2):1998;307-310.
94. Augusti. Therapeutic values of onion (Allium cepa L.) and garlic (Allium sativum L.) [Review]. Indian J Exp Biol. 34:(7):1996;634-640.
95. Agarwal K. Therapeutic actions of garlic constituents [Review]. Med Res Rev. 16:(1):1996;111-124.
96. Silagy C., Neil H. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 12:1994;463-468.
97. Silagy C., Neil A. Garlic as a lipid lowering agent, a meta-analysis. J R Coll Physicians Lond. 28:1994;2-8.
98. Steiner M., Khan A., Holbert D., Lin R. A double-blind crossover study in moderately hypercholesterolemic men that compared the effects of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr. 64:(6):1996;866-870.
99. Dausch J., Nixon D. Garlic: A review of its relationship to malignant disease. Prevent Med. 19:1990;346-361.
100. Lau B., Tadi P., Tosk J. Allium sativum (garlic) and cancer prevention. Nutr Res. 10:1990;937-948.
101. Belman S. Onion and garlic oils inhibit tumor progression. Carcinogenesis. 4:1983;1063-1065.
102. Belman S. Onion and garlic oils inhibit tumour progression. Carcinogenesis. 4:1983;1063-1065.
103. Schaffer E.M., Liu J.Z., Green J., Dangler C.A., Milner J.A. Garlic and associated allyl sulfur components inhibit N-methyl-N- nitrosourea induced rat mammary carcinogenesis. Cancer Lett. 102:(1-2):1996;199-204.
104. Cheng J.Y., Meng C.L., Tzeng C.C., Lin J.C. Optimal dose of garlic to inhibit dimethylhydrazine-induced colon cancer. World J Surg. 19:(4):1995;621-625.
105. Sundaram S.G., Milner J.A. Diallyl disulfide suppresses the growth of human colon tumor cell xenografts in athymic nude mice. J Nutr. 126:(5):1996;1355-1361.
106. Ip C., Lisk D.J., Thompson H.J. Selenium-enriched garlic inhibits the early stage but not the late stage of mammary carcinogenesis. Carcinogenesis. 17:(9):1996;1979-1982.
107. Schaffer E.M., Liu J.Z., Milner J.A. Garlic powder and allyl sulfur compounds enhance the ability of dietary selenite to inhibit 7,12-dimethylbenz [a]anthracene-induced mammary DNA adducts. Nutrition & Cancer. 27:(2):1997;162-168.
108. Amagase H., Schaffer E.M., Milner J.A. Dietary components modify the ability of garlic to suppress 7,12-dimethylbenz(a) anthracene-induced mammary DNA adducts. J Nutr. 126:(4):1996;817-824.
109. Maurya A., Singh S. Differential induction of glutathione transferase isoenzymes of mice stomach by diallyl sulfide, a naturally occuring anticarcinogen. Cancer Lett. 57:1991;121-129.
110. Hatono S., Jimenez A., Wargovich M. Chemopreventive effect of S-allylcysteine and its relationship to the detoxification enzyme glutathione S-transferase. Carcinogenesis. 17:(5):1996;1041-1044.
111. Hu X., Benson P., Srivastava S., et al. Glutathione S-transferases of female A/J mouse liver and forestomach and their differential induction by anti-carcinogenic organosulfides from garlic. Arch Biochem Biophys. 336:(2):1996;199-214.
112. Steinmatz K., Kushi L., Bostick R., Folsom A., Potter J. Vegetables, fruit, and colon cancer in the Iowa Women's Health Study. Am J Epidemiol. 139:(11):1994;1-15.
113. Shenoy N., Choughuley A. Inhibitory effect of diet related sulphydryl compounds on the formation of carcinogenic nitrosamines. Cancer Lett. 65:1992;227-232.
114. Ernst E. Can Allium vegetables prevent cancer. Phytomedicine. 4:(1):1997;79-83.
115. Dorant E., van den Brandt P., Goldbohlm R. A prospective cohort study on the relationship between onion and leek consumption, garlic supplement use and the risk of colorectal carcinoma in the Netherlands. Carcinogensis. 17:(3):1996;477-484.
116. German K., Kumar U., Blackford H.N. Garlic and the risk of TURP bleeding. Br J Urol. 76:(4):1995;518.
117. Burnham B.E. Garlic as a possible risk for postoperative bleeding [letter] [see comments]. Plastic Reconstr Surg. 95:(1):1995;213.
118. Sunter W. Warfarin and garlic. Pharm J. 246:1991;72.
119. Fulder S. Garlic and the prevention of cardiovascular disease. Cardiology in Practice. 3:(30):1989;34-35.
120. Brinker F. The Hoxsey treatment: Cancer quackery or effective physiological adjuvant. J Naturopath Med. 6:(1):1996;9-22.
121. Austin S., Hitchcock C. Breast Cancer: what you should know about prevention, diagnosis and treatment. 1994;Prima Publishing, Rocklin,CA.
122. Zani F., Cuzzoni M., Daglia M., Benvenuti S., Vampa G., Mazza P. Inhibition of mutagenicity in Salmonella typhimurium by Glycyrrhiza glabra extract, glycyrrhizinic acid, 18 alpha and 18 beta-glycyrrhetinic acids. Planta Med. 59:(6):1993;502-507.
123. Kitagawa K., Nishino H., Iwashima A. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-stimulated 3-O-methyl-glucose transport in mouse Swiss 3T3 fibroblasts by glycyrrhetic acid. Cancer Lett. 24:1984;157-163.
124. Nishino H., Kitagawa K., Fujika H., Iwashima A. Berberine sulphate inhibits tumour-promoting activity of telecidin in two stage carcinogenesis on mouse skin. Oncology. 43:1986;131-134.
125. Zhang R., Dougherty D., Rosenblum M. Laboratory studies of berberine used alone and in combination with 1,3- Bis (2-chloroethyl-1-nitrosurea) to treat malignant brain tumours. Chinese Medicine Journal. 103:(8):1990;658-665.
126. Wang H., Zheng Q. Effects of Phytolacca acinosa polysaccharides I with different schedules on its antitumor efficiency in tumor bearing mice and production of IL-1, IL-2, IL-6 TNF, CSF activity in normal mice. Immunopharmacol Immunotoxicol. 19:(2):1997;197-213.
127. Zhang J., Qian D. Antitumor activity and tumor necrosis factor production of Phytolacca acinosa polysaccharides I in mice [Abstract]. Chung Kuo Yao Li Hsueh Pao. 14:(6):1993;542-545.
128. Austin S., Baumgartner Dale E., DeKadt S. Long term follow up of cancer patients using Contreras. Hoxsey and Gerson formulas. Journal of Naturopathic Medicine. 5:(1):1994;74-76.
129. Iscador. An information package. 1996;The Canadian Breast Cancer Research Initiative, Toronto, ON.
130. Jung M., Baudino S. Characterization of cytotoxic proteions from mistletoe (Viscum albumL). Cancer Lett. 51:1990;103-108.
131. Hajto T., Lanzrein C. Natural killer and antibody-dependent cell mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album treated breast cancer patients. Oncology. 43:1986;93-97.
132. Leroi-Von May A. Progress in iscador therapy of malignant tumours. Homoeopathic Heritage. Summer:1998;208-217.
133. Leroi R. Iscador treatment of carcinoma. Homoeopathic Heritage. May:1996;283-289.
134. Chernyshov V., Omelchenko L., Heusser P., et al. Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complement Ther Med. 5:1997;141-146.
135. Kleijnen J., Knipschild P. Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine. 1:1994;225-260.
136. Keine H. Clinical studies on mistletoe therapy for cancerous diseases, review. Therapeutikon. 3:1989;347-353.
137. Locock R. Mistletoe. Canadian Pharmaceutical Journal. March:1986;125-127.
138. Eisenberg D.M., Kessler R.C., Foster C., Norlock F.E., Calkins D.R., Delbanco T.L. Unconventional medicine in the United States: Prevalence, costs and patterns of use. New Engl J M. 328:(4):1993;246-252.
139. Stewart M., Brown J.B., Weston W.W., McWhinney I.R., McWilliam C.L., Freeman T.R. Patient-centred medicine. Transforming the clinical method. 1995;Sage Publications, London.
140. Boon H., Austin Z., Busto U., Chin T., Paton T., Sinnott P. The role of the pharmacist with respect to natural health products. 1999;The Canadian Association of Hospital Pharmacists Task Force on Complementary/Alternative Medicine, Ottawa.
141. Eisenberg D. Advising patients who seek alternative medical therapies. Ann Int Med. 127:(1):1997;61-69.